

### HELIUS MEDICAL TECHNOLOGIES GRANTS STOCK OPTIONS

(Newtown PA) – March 16, 2015 – Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) (“Helius” or “the Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 100,000 shares of the Company, to a director of Helius.

All options are subject to any earlier termination in accordance with their terms. The options are exercisable at a price of CAD \$3.20, with one-third of such options vesting on the date of grant, another one-third vesting on the 1st anniversary of the date of grant and the final one-third vesting on the 2nd anniversary of the date of grant.

#### **About Helius Medical Technologies**

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to use unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company intends to file for U.S. Food and Drug Administration clearance of the PoNS™ device. For more information, please visit <http://www.heliusmedical.com>.

#### **Cautionary Disclaimer Statement:**

*The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.*

#### **Safe Harbor Statement**

*All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include risks detailed from time to time in the filings made by the Company with securities regulators.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the*

*date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.*

# # #

**Corporate Contact:**

Phil Deschamps

614-596-2597

[pdeschamps@heliusmedical.com](mailto:pdeschamps@heliusmedical.com)

**US Investor Relations Contact**

Todd James

646-378-2926

[tjames@troutgroup.com](mailto:tjames@troutgroup.com)

**Canadian Investor Relations:**

778-588-7144

[info@heliusmedical.com](mailto:info@heliusmedical.com)

**Media Contact:**

Becky Kern

914-772-2310

[bkern@heliusmedical.com](mailto:bkern@heliusmedical.com)